Sequencing of Checkpoint or BRAF/MEK Inhibitors on Brain Metastases in Melanoma

Abstract excerpt

BACKGROUND: V600-mutant melanoma is unknown. The SECOMBIT trial examined the impact of the order of receipt of these treatments in such patients. METHODS: In this three-arm trial, we reviewed patients without brain metastases who received the BRAF/MEK inhibitors encorafenib and binimetinib until they had progressive disease followed by the immune checkpoint inhibitors ipilimumab and nivolumab (arm A); or...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Brain Metastases and Treatment
• Share to Cutaneous Melanoma Detection and Management
• Share to Melanoma and MAPK Pathways